MA33360B1 - Composés antiviraux hétérocycliques - Google Patents

Composés antiviraux hétérocycliques

Info

Publication number
MA33360B1
MA33360B1 MA34447A MA34447A MA33360B1 MA 33360 B1 MA33360 B1 MA 33360B1 MA 34447 A MA34447 A MA 34447A MA 34447 A MA34447 A MA 34447A MA 33360 B1 MA33360 B1 MA 33360B1
Authority
MA
Morocco
Prior art keywords
antiviral compounds
heterocyclic antiviral
heterocyclic
compounds
inhibitors
Prior art date
Application number
MA34447A
Other languages
Arabic (ar)
English (en)
Inventor
Vicente Fidalgo Javier De
Jim Li
Ryan Craig Schoenfeld
Francisco Xavier Talamas
Joshua Paul Gergely Taygerly
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33360B1 publication Critical patent/MA33360B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION A POUR OBJET DES COMPOSÉS AYANT LA FORMULE (I), R1, R2, R3, R4, X1, X2, X3 ET X4 ÉTANT TELS QUE DÉFINIS ICI, QUI SONT DES INHIBITEURS DE LA POLYMÉRASE NS5B DU VIRUS DE L'HÉPATITE C. LA PRÉSENTE INVENTION CONCERNE AUSSI DES COMPOSITIONS ET DES PROCÉDÉS POUR LE TRAITEMENT D'UNE INFECTION AU VHC ET L'INHIBITION DE LA RÉPLICATION DU VHC.
MA34447A 2009-06-09 2010-06-08 Composés antiviraux hétérocycliques MA33360B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18546009P 2009-06-09 2009-06-09
US26335109P 2009-11-21 2009-11-21
PCT/EP2010/057958 WO2010142656A1 (fr) 2009-06-09 2010-06-08 Composés antiviraux hétérocycliques

Publications (1)

Publication Number Publication Date
MA33360B1 true MA33360B1 (fr) 2012-06-01

Family

ID=42288900

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34447A MA33360B1 (fr) 2009-06-09 2010-06-08 Composés antiviraux hétérocycliques

Country Status (25)

Country Link
US (2) US8026253B2 (fr)
EP (1) EP2440528B1 (fr)
JP (1) JP5612678B2 (fr)
KR (1) KR101431343B1 (fr)
CN (1) CN102803216B (fr)
AR (1) AR077004A1 (fr)
AU (1) AU2010257592B2 (fr)
BR (1) BRPI1010852A2 (fr)
CA (1) CA2764141C (fr)
CO (1) CO6400218A2 (fr)
CR (1) CR20110605A (fr)
EC (1) ECSP11011513A (fr)
ES (1) ES2525254T3 (fr)
HK (1) HK1176070A1 (fr)
IL (1) IL216412A (fr)
MA (1) MA33360B1 (fr)
MX (1) MX2011013209A (fr)
MY (1) MY157435A (fr)
NZ (1) NZ596646A (fr)
PE (2) PE20151092A1 (fr)
RU (1) RU2540332C2 (fr)
SG (1) SG176762A1 (fr)
TW (1) TWI428332B (fr)
WO (1) WO2010142656A1 (fr)
ZA (1) ZA201108921B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174252A1 (en) * 2009-03-06 2011-10-28 Hoffmann La Roche Heterocyclic antiviral compounds
RU2572558C2 (ru) * 2010-07-07 2016-01-20 Ф. Хоффманн-Ля Рош Аг Противовирусные гетероциклические соединения
RU2572835C2 (ru) * 2010-08-13 2016-01-20 Ф. Хоффманн-Ля Рош Аг Производные (4-метилсульфониламинофенил)-хинолина, полезные при лечении гепатита с
WO2013090929A1 (fr) * 2011-12-15 2013-06-20 Gilead Sciences, Inc. Dérivés d'amino-quinoléine inhibiteurs de vhc
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2909193B1 (fr) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Modulateurs de ror-gamma-t de type quinolinyle à liaison phényle
CA2888210C (fr) 2012-10-16 2021-02-09 Janssen Pharmaceutica Nv Modulateurs de ror-gamma-t de type quinolinyle a liaison methylene
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9938292B2 (en) * 2014-03-24 2018-04-10 Guangdong Zhongsheng Pharmaceutical Co., Ltd Quinoline derivatives as SMO inhibitors
JP2018525371A (ja) * 2015-07-30 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アリール置換された二環式ヘテロアリール化合物
WO2021198981A1 (fr) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Composés antiviraux et leurs utilisations
CN111777549A (zh) * 2020-07-07 2020-10-16 中瀚(齐河县)生物医药科技有限公司 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB558009A (en) * 1942-05-08 1943-12-15 Harold Coates Quinoline derivatives
NZ235444A (en) * 1989-09-26 1992-07-28 Sumitomo Chemical Co Heterocyclically-substituted 1,2,3,6 tetrahydropyrimidine 2,6-diones, intermediates and herbicides
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
WO2001085172A1 (fr) * 2000-05-10 2001-11-15 Smithkline Beecham Corporation Nouveaux anti-infectieux
MX2010002318A (es) 2007-08-29 2010-03-22 Schering Corp Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
AU2008295476B2 (en) 2007-08-29 2013-08-01 Merck Sharp & Dohme Corp. 2, 3-Substituted Indole Derivatives for treating viral infections
JP5179585B2 (ja) 2007-08-29 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション 四環系インドール誘導体およびその使用法
MX2010002905A (es) 2007-09-17 2010-07-05 Abbott Lab Derivados de uracilo o timina para tratar la hepatitis c.
CN104628654A (zh) 2007-09-17 2015-05-20 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
ATE512954T1 (de) 2007-09-17 2011-07-15 Abbott Lab Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine
US8765757B2 (en) 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
CA2705587A1 (fr) 2007-11-16 2009-05-22 Schering Corporation Derives d'indole a substitution par aminosulfonyle en position 3 et leurs procedes d'utilisation
CN102448920B (zh) 2009-03-25 2016-04-06 Abbvie公司 抗病毒化合物和其用途
MX2011010047A (es) 2009-03-25 2011-10-11 Abbott Lab Compuestos antivirales y usos de los mismos.

Also Published As

Publication number Publication date
IL216412A0 (en) 2012-02-29
HK1176070A1 (zh) 2013-07-19
US8026253B2 (en) 2011-09-27
EP2440528B1 (fr) 2014-10-08
RU2011153788A (ru) 2013-07-20
JP5612678B2 (ja) 2014-10-22
US20110300103A1 (en) 2011-12-08
CN102803216B (zh) 2016-04-06
CO6400218A2 (es) 2012-03-15
US8487103B2 (en) 2013-07-16
AU2010257592A1 (en) 2011-12-15
ECSP11011513A (es) 2012-01-31
EP2440528A1 (fr) 2012-04-18
MY157435A (en) 2016-06-15
CA2764141C (fr) 2016-11-15
PE20151092A1 (es) 2015-08-06
JP2012529461A (ja) 2012-11-22
AR077004A1 (es) 2011-07-27
SG176762A1 (en) 2012-01-30
RU2540332C2 (ru) 2015-02-10
TW201103906A (en) 2011-02-01
MX2011013209A (es) 2012-01-09
KR20120016675A (ko) 2012-02-24
WO2010142656A1 (fr) 2010-12-16
IL216412A (en) 2015-01-29
AU2010257592B2 (en) 2014-11-13
CA2764141A1 (fr) 2010-12-16
PE20120937A1 (es) 2012-08-01
CR20110605A (es) 2012-02-09
CN102803216A (zh) 2012-11-28
BRPI1010852A2 (pt) 2019-09-24
TWI428332B (zh) 2014-03-01
US20100311760A1 (en) 2010-12-09
ES2525254T3 (es) 2014-12-19
KR101431343B1 (ko) 2014-08-19
NZ596646A (en) 2014-01-31
ZA201108921B (en) 2014-05-28

Similar Documents

Publication Publication Date Title
MA33360B1 (fr) Composés antiviraux hétérocycliques
MA30198B1 (fr) Inhibiteurs de la protease ns3 du vhc
MA30893B1 (fr) Inhibiteurs de la protease ns3 du vhc
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
MA37942B1 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
EA201170241A1 (ru) Макроциклические хиноксалиновые соединения в качестве ингибиторов протеазы вгс ns3
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MY159958A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
DE602007006796D1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
MX2012008443A (es) Nucleosidos antiviricos.
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
DK1987038T3 (da) HCV NS5B-hæmmere
MX2012003170A (es) Compuestos heterociclicos antivirales.
MY150667A (en) Antiviral nucleosides
ATE546460T1 (de) Hemmer des hepatitis-c-virus
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
EA200900676A1 (ru) Ингибиторы вируса гепатита с
EA200701849A1 (ru) Пролекарственные соединения трициклических нуклеозидов, фармацевтическая композиция на их основе и способ лечения и/или ингибирования вирусной инфекции у млекопитающего
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
ATE533771T1 (de) Cyclopropylkondensierte indolobenzazepine als hcv-ns5b-inhibitoren
MA32006B1 (fr) Inhibiteurs de polymerase virale
MA37992A1 (fr) Composes inhibiteurs de protéase ns3 pour une utilisation dans le traitement de l’infection par le virus de l'hépatite c.
MX2011012541A (es) Compuestos heterociclicos antivirales.
BRPI1016167A2 (pt) compostos heterocíclicos antivirais.